Aducanumab looms larger after Biogen cuts guidance, shelves programs in MS and SMA 

As Biogen revealed the submission of its Alzheimer’s therapy aducanumab to regulators in a second major territory, a series of other disclosures in its 3Q20 earnings announcement suggest its reliance on the mAb for future growth is even greater than previously anticipated.

Biogen Inc. (NASDAQ:BIIB) said Tuesday that it has submitted an MAA for aducanumab to EMA to treat Alzheimer’s disease. The anti-β amyloid mAb is already under a closely-watched FDA review, with an advisory committee meeting to take place next month...